These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

838 related items for PubMed ID: 1423949

  • 1. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB.
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [Abstract] [Full Text] [Related]

  • 2. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC, Morton BC, Green MS, Tang AS.
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [Abstract] [Full Text] [Related]

  • 3. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA, Kluger J, White CM.
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [Abstract] [Full Text] [Related]

  • 4. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R.
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [Abstract] [Full Text] [Related]

  • 5. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia.
    Tran HT, Chow MS, Kluger J.
    Pacing Clin Electrophysiol; 1997 Sep; 20(9 Pt 1):2275-8. PubMed ID: 9309756
    [Abstract] [Full Text] [Related]

  • 6. [Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects].
    van de Loo A, Klingenheben T, Hohnloser SH.
    Z Kardiol; 1994 Dec; 83(12):887-90. PubMed ID: 7846927
    [Abstract] [Full Text] [Related]

  • 7. [Amiodarone-induced torsade de pointes--five case reports].
    Kukla P, Słowiak-Lewińska T.
    Kardiol Pol; 2004 Apr; 60(4):365-70; discussion 371. PubMed ID: 15226788
    [Abstract] [Full Text] [Related]

  • 8. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G.
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [Abstract] [Full Text] [Related]

  • 9. Intravenous amiodarone homogeneously prolongs ventricular repolarization in patients with life-threatening ventricular tachyarrhythmia.
    Kotake Y, Kurita T, Akaiwa Y, Yasuoka R, Motoki K, Kobuke K, Iwanaga Y, Miyazaki S.
    J Cardiol; 2015 Aug; 66(2):161-7. PubMed ID: 25468767
    [Abstract] [Full Text] [Related]

  • 10. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
    Mattioni TA, Zheutlin TA, Sarmiento JJ, Parker M, Lesch M, Kehoe RF.
    Ann Intern Med; 1989 Oct 01; 111(7):574-80. PubMed ID: 2774388
    [Abstract] [Full Text] [Related]

  • 11. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
    Glatter K, Yang Y, Chatterjee K, Modin G, Cheng J, Kayser S, Scheinman MM.
    Circulation; 2001 Jan 16; 103(2):253-7. PubMed ID: 11208685
    [Abstract] [Full Text] [Related]

  • 12. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S, Rao ML, Schröder R, Lüderitz B, Bauriedel G.
    Dtsch Med Wochenschr; 2001 Dec 07; 126(49):1396-400. PubMed ID: 11740632
    [Abstract] [Full Text] [Related]

  • 13. Physiological and pathological responses of TU waves to class Ia antiarrhythmic drugs.
    Maruyama T, Ohe T, Kurita T, Aihara N, Shimizu W.
    Eur Heart J; 1995 May 07; 16(5):667-73. PubMed ID: 7588899
    [Abstract] [Full Text] [Related]

  • 14. Torsade de pointes in initiating hemodialysis: a case report.
    Yang JA, Choi HS, Bae EH, Ma SK, Kim SW, Kim CS.
    Ann Palliat Med; 2020 May 07; 9(3):1264-1268. PubMed ID: 32389016
    [Abstract] [Full Text] [Related]

  • 15. Drug-induced torsade de pointes.
    Raehl CL, Patel AK, LeRoy M.
    Clin Pharm; 1985 May 07; 4(6):675-90. PubMed ID: 2416504
    [Abstract] [Full Text] [Related]

  • 16. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A, Rudas L, Liszkai G, Fazekas T.
    Orv Hetil; 2003 Feb 02; 144(5):241-7. PubMed ID: 12647553
    [Abstract] [Full Text] [Related]

  • 17. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.
    Antzelevitch C.
    Heart Rhythm; 2005 Nov 02; 2(2 Suppl):S9-15. PubMed ID: 16253930
    [Abstract] [Full Text] [Related]

  • 18. Torsade de pointes induced by intravenous amiodarone therapy accompanied by marked augmentation of the transmural dispersion of repolarization in a patient with tachycardia-induced-cardiomyopathy.
    Yonai R, Kawabata M, Maeda S, Kawashima T, Tsuda Y, Nakasone T, Nakane H, Hirao K.
    Ann Noninvasive Electrocardiol; 2021 May 02; 26(3):e12810. PubMed ID: 33070441
    [Abstract] [Full Text] [Related]

  • 19. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS, Zehender M, Just H.
    Drug Saf; 1994 Dec 02; 11(6):463-76. PubMed ID: 7727055
    [Abstract] [Full Text] [Related]

  • 20. A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.
    Katapadi K, Kostandy G, Katapadi M, Hussain KM, Schifter D.
    Angiology; 1997 Sep 02; 48(9):821-6. PubMed ID: 9313632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.